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Objective. Rheumatoid arthritis (RA) may be complicated by different infections, but risk factors for these are not fully elucidated.
Here, we assessed the incidence of and risk factors for infections requiring hospitalization (IRH) including pneumocystis
pneumonia (PCP) in patients with RA.Methods.We retrospectively surveyed all RA patients treated at our hospital from 2009 to
2013, for whom data were available on demographic features, medications, comorbidities, and severity of RA. Multivariate logistic
regression analysis was applied to calculate adjusted odds ratios (ORs) for factors associated with the occurrence of IRH. Results.
In a total of 9210 patient-years (2688 patients), there were 373 IRH (3.7/100 patient-years). Respiratory tract infections were most
frequent (𝑛 = 154, and additionally 16 PCP), followed by urinary tract infections (𝑛 = 50). Significant factors for PCP included
higher age (≥70 years; OR 3.5), male sex (6.6), underlying lung disease (3.0), use of corticosteroids (4.8), and use of biologics (5.4).
Use of methotrexate (5.7) was positively associated with PCP but negatively with total infections (0.7). Additionally, functional
disorders and higher RA disease activity were also related to total infections. Conclusions. Risk factors for infection should be taken
into account when deciding treatment for the individual RA patient.
1. Introduction
Biological and other recently developed agents for treating
rheumatoid arthritis (RA) now facilitate control of disease
activity in many patients. Recent therapeutic recommenda-
tions include the use of these drugs, despite the fact that
such potent new therapies, like the corticosteroids used for
many years, can cause serious infection by virtue of their
immunosuppressive activity. Thus, infection rates in RA
patients are reported to be almost twice those of the general
population [1] and infectious pneumonia is a common cause
of death in RA [2, 3]. On the other hand, RA itself is
generally not lethal, except under certain conditions such
as aggravated lung involvement. It is therefore important
to distinguish iatrogenic effects from disease pathology. In
particular, pneumocystis pneumonia (PCP) more commonly
seen in AIDS is a life-threatening infection even in human
immunodeficiency virus- (HIV-) negative patients (including
RA patients) with a mortality rate higher than in HIV-
positive patients [4, 5]. Potent therapies for RA can cause
lethal infections, especially in elderly patients or those with
comorbidities. Clinicians should ideally be able to estimate
the risk and benefit of a particular treatment and match this
to an optimal individualized therapy for each RA patient. To
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this end, we investigated the incidence of infections requiring
hospitalization (IRH), including PCP, and factors related to
their occurrence in a cohort of RA patients.
2. Materials and Methods
2.1. Patients. Every patient with RA who visited Sagamihara
National Hospital from April 2009 to March 2013 was
enrolled in this study and their clinical information was
retrospectively obtained from their medical records. All the
subjectsmet the standard diagnostic criteria for RA [6, 7].The
data on all patients have been obtained every year by means
of an open prospective cohort registry, which meant that not
only fixed patientswere continuously followed and registered,
but the accumulation of patient data collected every year was
analyzed using patient-yearmethod.This studywas approved
by Sagamihara National Hospital Research Ethics Commit-
tee. Patients receiving JAK inhibitors (e.g., tofacitinib) or
any biologics other than infliximab, etanercept, adalimumab,
golimumab, tocilizumab, or abatacept were excluded because
they were too few in number for meaningful stratification.
Patients on clinical trial or taking over the recommended
dose of biologics were also excluded.
2.2. Clinical Information. In multivariate analysis of risk
factors for each IRH, the following parameters were assessed:
age, sex, RA disease duration, and RA disease activity
score in 28 joints with erythrocyte sedimentation rate
(DAS28-ESR), Steinbrocker’s stage score, global functional
status, underlying lung disease, renal function, use of nons-
teroidal anti-inflammatory drugs (NSAIDs), corticosteroids,
methotrexate (MTX), bucillamine, or salazosulfapyridine,
and the above-mentioned biologics and immunosuppress-
ants (tacrolimus, azathioprine, mizoribine, cyclophospham-
ide, or cyclosporine). In Japan, tacrolimus is the most
common immunosuppressant used to treat RA; the biologics
included all that had been approved for RA by 2012.The stage
of articular destruction was classified from radiographs of
the hands based on Steinbrocker’s classification (Stage) [8].
Global functional status (Class) was based on classification by
the American College of Rheumatology 1991 revised criteria
[9]. Estimated glomerular filtration rate (eGFR) as a measure
of renal function was calculated from the serum creatinine
level using equations developed by the Japanese Society of
Nephrology [10]. Patients with an eGFR < 60ml/min/1.73m2
were regarded as having renal dysfunction. Underlying lung
disease was identified by computed tomography (CT) of the
lung during the study period; patients who did not undergo
CTwere regarded as being free of lung disease. CT of the lung
was performed in 35.8% of the patient cohort. Annual clinical
information was averaged from regular visits over the year,
whereas IRH were recognized at hospitalization or for other
events including infection occurring outside of regular visits.
Diagnosis of individual infections was based on clinical
and laboratory findings. PCP was diagnosed when a patient
with fever and/or nonproductive cough had progressive
hypoxemia, ground glass opacity of the lung detected by CT,
and positivity for Pneumocystis jirovecii in the sputum by
PCR, or elevated serum (1-3)-𝛽-D-Glucan, as described in
previous studies [11, 12].
2.3. Statistical Analysis. Between-groups comparisons for
univariate analysis were conducted using Student’s 𝑡-test or
Wilcoxon rank sum test for continuous variables or Fisher’s
exact test for categorical variables. 𝑝 values < 0.05 were
considered significant. Associations of relevant factors with
each particular infection were estimated using multivariate
analysis with multiple logistic regression. To select variables
for multivariate analysis, stepwise regression was applied and
only significant variables were employed for the analysis.
The Wald test was used to assess the significance of each
factor. Threshold values of variables such as age and DAS28-
ESR were calculated by univariate analysis using receiver
operating characteristic (ROC) curves. For infections with
which the use of corticosteroids was significantly associated
in multivariate analysis, threshold doses of corticosteroids
(prednisolone equivalents) were calculated in a similar man-
ner.
3. Results
3.1. Patient Demographics. Table 1 shows the characteris-
tics of patients with or without infection given as patient-
years. In the whole cohort of 2688 patients (9210 patient-
years), 274 patients suffered 373 IRH. Fifty-four had multiple
such infections in different years. The overall rate of IRH
was 3.7 per 100 patient-years; 11.5% had renal dysfunction
(eGFR < 60ml/min/1.73m2) with 3.3% having an eGFR <
45ml/min/1.73m2. Relative to patients without infection, fac-
tors identified by univariate analysis as potentially associated
with IRH were female sex, higher age, longer RA disease
duration, higher rheumatoid factor, having renal dysfunc-
tion, having lung disease, higher RA disease activity, higher
stage of RA, lower functional status, and having been treated
with corticosteroids, biologics, or immunosuppressants (with
the exception of MTX).
3.2. Sites and Types of Infections. Figure 1 illustrates the sites
and types of IRH present in these patients. Simultaneous
multiple infections are recorded as separate events. PCP
and tuberculosis are listed separately from respiratory tract
infections, and herpes zoster (HZ) is listed separately from
skin and soft tissue infections in the figure. “Others” include
8 other viral infections and 5 tuberculosis patients. The
respiratory tract was the most frequent site of infection (𝑛 =
154, 41.3%) followed by the urinary tract (𝑛 = 50, 13.4%),
gastrointestinal tract including biliary tract (𝑛 = 41, 11.0%),
skin and soft tissue (𝑛 = 32, 8.6%), HZ (𝑛 = 21, 5.6%), and
PCP (𝑛 = 16, 4.3%). Incidence rates of all infections and of
the common infections are summarized in Table 2.
Sixteen patients suffered from PCP; none had received
any prophylaxis. All had been treated with either corticos-
teroids (𝑛 = 14) or MTX (𝑛 = 13). Biologics had been
administered to 6 patients (one each receiving infliximab,
golimumab, or abatacept and three with adalimumab). Dura-
tion of treatment with these biologics before the onset of PCP
ranged from 2 to 8 months (median 3 months).
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Table 1: Characteristics of patients with or without infections.
Without infection (2414 pts) With infection (274 pts) 𝑝 value
Female 83.9% 73.7% <0.0001
Age, years, mean (SD) 63.7 (12.3) 70.4 (9.9) <0.0001
Over 70 years of age 34.4% 60.2% <0.0001
Disease duration of RA, years, median (IQR) 12 (5–22) 16 (9–26) <0.0001
Rheumatoid factor, mean, U/ml 142.2 240.1 <0.0001
eGFR, mL/min/1.73m2, median (IQR) 80 (70–95) 75 (60–95.5) 0.002
eGFR < 60 mL/min/1.73m2 11.1% 22.6% <0.0001
Underlying lung disease 14.9% 50.0% <0.0001
DAS28-ESR, mean ± SD 3.1 ± 1.1 3.7 ± 1.2 <0.0001
Stage III or IV 48.5% 70.1% <0.0001
Class III or IV 14.6% 47.8% <0.0001
Treated with corticosteroids (median dose, mg/day) 51.8% (3.75) 85.4% (5) <0.0001
Treated with MTX (median dose, mg/week) 59.6% (8) 40.4% (8) <0.0001







Treated with immunosuppressants 7.9% 13.2% 0.001
eGFR, estimated glomerular filtration rate; DAS28-ESR, disease activity score in 28 joints with erythrocyte sedimentation rate; Stage, Steinbrocker’s
radiographic stage score; Class, global functional status; NSAIDs, nonsteroidal anti-inflammatory drugs; MTX, methotrexate. Dose of corticosteroids is






















Figure 1: Sites and types of infections. Gastrointestinal tract includes biliary tract.
3.3. Risk Factors. Table 2 shows the significant risk factors
and odds ratios (ORs) with 95% confidence intervals (CIs) for
individual infections estimated using multivariate analysis.
Threshold values of age (70 years) and DAS28-ESR (3.8)
were calculated by univariate analysis using ROC curves.
Threshold doses of corticosteroids for individual infections
were similarly estimated. Significant risk factors for any
infection were age ≥ 70 years, male sex, Class III or IV,
having underlying lung disease, DAS28-ESR ≥ 3.8, use of
corticosteroids, and use of biologics. Use of corticosteroids
was a significant risk factor for any infection and for common
infections, whereas use of MTX was significantly associated
with a reduced risk for most infections except for PCP. Fur-
thermore, no significant difference was found in background
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Table 2: Significant risk factors and the odds ratios for each infection.
Total (𝑛 = 342, 3.7/100 PY) OR (95% CI) 𝑝 value
Age 70 and older 1.5 (1.2–2.0) 0.002
Male 1.6 (1.1–2.2) 0.004
Class III or IV 2.2 (1.7–3.0) <0.0001
Underlying lung disease 3.1 (2.3–4.2) <0.0001
DAS28-ESR ≥ 3.8 1.7 (1.3–2.3) 0.0001
Corticosteroids 3.0 (2.1–4.4) <0.0001 ∗2.00mg/day
Biologics 1.4 (1.0–2.0) 0.033
Methotrexate 0.7 (0.6–1.0) 0.034
Respiratory tract (𝑛 = 154, 1.7/100 PY) OR (95% CI) 𝑝 value
Age 70 and older 1.5 (1.0–2.1) 0.031
Male 2.5 (1.7–3.6) <0.0001
Class III or IV 2.6 (1.8–3.7) <0.0001
Underlying lung disease 5.1 (3.5–7.4) <0.0001
Corticosteroids 2.5 (1.6–4.0) 0.0001 ∗2.50mg/day
Methotrexate 0.7 (0.5–1.0) 0.049
Urinary tract (𝑛 = 50, 0.5/100 PY) OR (95% CI) 𝑝 value
Female 3.9 (1.2–23.9) 0.062
Class III or IV 7.6 (4.0–15.0) <0.0001
eGFR < 60ml/min/1.73m2 2.2 (1.2–4.1) 0.013
Corticosteroids 3.8 (1.6–11.2) 0.006 ∗1.85mg/day
Methotrexate 0.5 (0.3–0.9) 0.028
Gastrointestinal tract (𝑛 = 41, 0.4/100 PY) OR (95% CI) 𝑝 value
Age 70 and older 4.0 (2.0–9.2) 0.0004
Class III or IV 3.4 (1.7–6.8) 0.0004
Corticosteroids 4.5 (1.7–15.4) 0.005 ∗1.85mg/day
Skin and soft tissue (𝑛 = 32, 0.3/100 PY) OR (95% CI) 𝑝 value
Class III or IV 4.1 (1.9–8.8) 0.0002
Corticosteroids 3.0 (1.2–9.0) 0.033 ∗1.75mg/day
Methotrexate 0.4 (0.2–0.9) 0.025
Herpes zoster (𝑛 = 21, 0.2/100 PY) OR (95% CI) 𝑝 value
Corticosteroids 5.3 (1.8–22.8) 0.007 ∗3.75mg/day
PCP (𝑛 = 16, 0.2/100 PY) OR (95% CI) 𝑝 value
Age 70 and older 3.5 (1.2–10.8) 0.025
Male 6.6 (2.4–19.0) 0.0003
Underlying lung disease 3.0 (1.0–8.6) 0.038
Corticosteroids 4.8 (1.3–31.0) 0.039 ∗5.00mg/day
Biologics 5.4 (1.7–15.7) 0.002
Methotrexate 5.7 (1.8–25.9) 0.008
PY, patient-years; OR, odds ratio; CI, confidence interval; Class, global functional status; PCP, Pneumocystis pneumonia. ∗Threshold dose of corticosteroids
(prednisolone equivalents).
factors when comparing 54 patients with multiple infections
with 220 patients with only one infection.
Higher RA disease activity (DAS28-ESR ≥ 3.8) was a
risk factor for any infection, as was renal dysfunction (eGFR
< 60ml/min/1.73m2) for urinary tract infection. The only
significant risk factor for HZ was use of corticosteroids. We
also analyzed each of the 6 biologics separately or as a group
of tumor necrosis factor- (TNF-) directed versus not TNF-
directed biologics as a variable for any infections but found
no significant correlations (data not shown).
Significant risk factors for PCP were age ≥ 70 years, male
sex, having underlying lung disease, use of corticosteroids,
use of biologics, and use of MTX. Of 16 patients with PCP,
all had three or more risk factors and 11 patients (68.8%)
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had received corticosteroids and MTX simultaneously. Clas-
sifying every patient-year with ≥3 risk factors including
corticosteroids and MTX as having a high risk for PCP, the
sensitivity, specificity, and positive and negative predictive
values for PCP were estimated as 68.8%, 81.7%, 0.7%, and
99.9%, respectively.
4. Discussion
Risk factors for any type of infection in RApatients, especially
those associated with the use of biologics, have been well-
investigated, but few studies have described the individual
incidence of the different common infections and their
related susceptibility factors. Accordingly, here we identified
the most frequent sites for and types of IRH and the
associated risk factors for these in a cohort of RA patients.
It is important to note that the characteristics of the RA
patients in our cohort correspond well to those described for
the ten-year cumulative dataset from the largest nationwide
Japanese multicenter cohort of RA patients (NinJa, the
National Database of Rheumatic Disease by iR-net in Japan
registry) [13], implying that our cohort is representative of
the overall situation of RA patients in Japan. In this cohort,
the rate of hospitalization for infections (3.7/100 patient-
years) was fairly similar to previous reports (approximately
1 to 10 per 100 patient-years) with several factors accounting
for variability, such as heterogeneity among the cohorts and
decisions for hospitalization [1, 14–20]. Our results confirmed
established data that the most frequent infection site in RA
patients is the respiratory tract, accounting for approximately
one-third to one-half of all infections [1, 14, 16, 18, 19, 21, 22].
Similarly, the next most frequent infection sites were the
urinary tract, skin and soft tissue (including HZ), and the
gastrointestinal tract [1, 14, 19, 22].
Numerous studies have noted different risk factors for
total serious infections in RA patients, attributed to three
major factors: immunological dysfunction resulting from RA
itself, organ involvement of RA and other comorbidities,
and immunosuppressive effects of medication [23]. These
are, however, related to each other and cannot be clearly
separated. Factors other than medications are also important
because frequent infections in RA patients have been a
problem since the presteroid era [24] and higher RA disease
activity assessed as increasingDAS28was reported to be asso-
ciated with IRH [15].Thus, Crowson et al. performed detailed
risk assessment scoring to predict serious infection and
reported that significant risk factorswere higher age, previous
serious infection, use of corticosteroids, elevated erythrocyte
sedimentation rate, extra-articular RA manifestations, and
comorbidities including coronary heart disease, heart failure,
peripheral vascular disease, chronic lung disease, diabetes
mellitus, or alcoholism [17].
As with the present study, earlier reports demonstrated
a significant risk of infection when using corticosteroids [14,
17, 21, 23]. In the present study, we calculated threshold doses
of corticosteroids for individual infections using univariate
analysis. The threshold dose of corticosteroids for PCP was
higher than for the other infections (Table 2), suggesting that
PCP develops only under highly immunosuppressed states in
RA patients.
Biologics are assumed to be contributing to the increased
susceptibility to infection in RA and numerous studies have
addressed this issue. A recent meta-analysis of 106 random-
ized trials found that use of standard-dose biologics was asso-
ciated with a slight but significantly increased risk for serious
infections (OR 1.31, 95% CI 1.09–1.58) relative to traditional
disease-modifying antirheumatic drugs (DMARDs) [20].
That OR is similar to our findings. The crucial factor here
may be the time after initiation of treatment with a biological
agent, with meta-analyses showing a significantly higher
risk of opportunistic infections in short-term (<6 months)
than in long-term studies [25], as well as a time-dependent
decreasing risk of serious infection from the use of anti-TNF
biologics [26]. The increased risk of infection when using
biologics seems to be absent after a year has passed.
Whether MTX contributes to increased susceptibility
to infection is still controversial. Some studies found an
increased risk [21, 27], while others did not [15, 28, 29], or
even reported a reduced risk as in our own results [14, 30].
Given that high RA disease activity predisposes to infection,
both anti-rheumatic and immunosuppressive effects of med-
ication need to be assessed. Immunosuppressive effects of
MTX, if any, will likely be offset by its activity in improving
immunological dysfunction caused byRA [31]. Of note, in the
present studyMTX use was associated with a reduced risk for
most infections but an increased risk solely for PCP. Previous
studies have also indicated associations between MTX use
and PCP [32, 33]; however, the detailed mechanism of the
PCP-specific risk of MTX use is unclear. MTX-induced total
lymphopenia or depletion of CD4+ cells may contribute to
some degree, but the majority of studies showed no signifi-
cant differences in peripheral blood total lymphocyte counts
between RA patients with or without PCP [5, 32–34]. In con-
trast to HIV-positive patients whose established risk for PCP
is a CD4+ cell count < 200 cells/𝜇L, RA patients with CD4+
cells > 200/𝜇L often suffer from PCP [5, 32]. It is proposed
that altered lymphocyte subsets other than general depletion
of CD4+ cells by MTX [35] as well as by immunosuppressive
therapies [36] may contribute to the development of PCP.
Postmarketing surveillance (PMS) reports in Japan
revealed that the incidence of PCP in RA patients treated
with biologics or iguratimod was approximately 0.1 to 0.3%
at 24 weeks or 6 months after the initiation of treatment,
respectively [37, 38]. Incidence estimated from the present
study (0.2/100 patient-years) is in line with these results.
Interestingly, the incidence of PCP reported from studies in
Western countries is less than in Japan. An investigation of
two US population-based hospitalization databases of RA
patients from 1996 to 2007 indicated an incidence of PCP
ranging from 0.6 to 4.0/100,000 patient-years without any
changes even after infliximab and etanercept began to be
commonly used for RA [39]. In the UK, data from the British
Society for Rheumatology Biologics Register for RA were
analyzed regarding incidence of PCP, which was reported to
range from 1.1 (with traditional synthetic DMARDs) to 2.0
(with anti-TNF biologics) per 10,000 patient-years [40]. As
mentioned above, RA patients probably have the highest risk
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of infections early after the initiation of biologics. Indeed,
the mean duration of administration of biologics before PCP
onset was 4 months in the present study and 9 weeks to
7.2 months in previous studies [12, 33, 41]. Although the
incidence derived fromPMS in Japan was for the period early
after the initiation of biologics or iguratimod, it is possible
that PCP is 10–100 times more frequent in Japan than in the
US or Europe.
In RA patients, established risk factors for PCP are higher
age, use of corticosteroids, and underlying lung disease
[12, 34, 42]. Higher age is a common contributor to PCP
as concluded by previous studies of RA using multivariate
analysis [12, 33, 42]. In general, higher age [43, 44], use of cor-
ticosteroids [45, 46], and chronic lung disease [47, 48] were
associated with colonization by P. jirovecii, which is found in
up to 55% of patients with chronic obstructive pulmonary
disease (COPD) [48] and 37.8% of patients with idiopathic
interstitial pneumonia [47]. Mori et al. performed molecular
testing for P. jirovecii on sputum or bronchoalveolar lavage
fluids of 82 patients with RA. Nine (10.9%) asymptomatic
carriers were identified, all of whom had received MTX [49].
Thus, MTX may facilitate colonization of P. jirovecii and be a
risk factor for PCP. Additionally, we identified male sex, use
of biologics, and use of MTX as risk factors, which might be
useful for considering prophylaxis for PCP.
In contrast to our results, Kourbeti et al. failed to show a
significant association of the use of biologics with PCP in a
meta-analysis (OR 1.77, 95% CI 0.42–7.47) [25]; however, this
does not necessarily imply a lack of association for several
reasons. In studies in Western countries, the number of
patients with PCPmay be too low to be powered to detect any
significant risk with biologics. Presumably, biologics confer
a high risk for PCP only shortly after treatment initiation.
Among studies comparing the incidence of PCP between RA
patients with or without biologics, most of the latter received
MTX, which might itself also predispose to PCP.
In addition to biases brought about by a retrospective
single-center study, the present study has some other lim-
itations. Information about smoking status, comorbidities
such as diabetes mellitus and cardiac disorders, and history
of previous infections was not available. To assess detailed
risks of using biologics on infection, the history of their use,
duration of administration, and dose should be included in
the analysis. DAS28-ESR at only one time point as considered
here (at one year) might be insufficient to fully evaluate
associations between RA disease activity and infection.
Sometimes PCP is hard to be distinguished from MTX or
RA induced interstitial pneumonia, which could influence
the risk estimation for PCP. Our study could not reveal any
general features of HZ in RA patients because we assessed
only hospitalized patients with HZ.
In conclusion, the present study documents the incidence
of and risk factors for individual infections in a cohort of
RA patients. The most frequent site of infection was the
respiratory tract, while PCP was not rare in patients without
prophylaxis. For both PCP and all infections, risk factors
included higher age, male sex, underlying lung disease, and
use of corticosteroids. Use of MTX was related only to PCP
and inversely to total and common infections. Relationships
between risks of infection, medication, and RA disease
activity are not easy to distinguish but need to be estimated in
order to provide the most appropriate treatment for infection
control in each individual RA patient.
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